RU2608644C2 - Антитела против белка рецептора с-мет - Google Patents

Антитела против белка рецептора с-мет Download PDF

Info

Publication number
RU2608644C2
RU2608644C2 RU2013125459A RU2013125459A RU2608644C2 RU 2608644 C2 RU2608644 C2 RU 2608644C2 RU 2013125459 A RU2013125459 A RU 2013125459A RU 2013125459 A RU2013125459 A RU 2013125459A RU 2608644 C2 RU2608644 C2 RU 2608644C2
Authority
RU
Russia
Prior art keywords
sequence
antibody
seq
human
variable domain
Prior art date
Application number
RU2013125459A
Other languages
English (en)
Russian (ru)
Other versions
RU2013125459A (ru
Inventor
Анна ХУЛТБЕРГ
Майкл СОНДЕРС
ХАРД Йоханнес ДЕ
Элс ФЕСТЬЕНС
ЙОНГЕ Натали ДЕ
Пауло МИКЬЕЛИ
Кристина Базилико
Торстен ДРАЙЕР
Original Assignee
арДЖЕН-ИКС Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by арДЖЕН-ИКС Н.В. filed Critical арДЖЕН-ИКС Н.В.
Publication of RU2013125459A publication Critical patent/RU2013125459A/ru
Application granted granted Critical
Publication of RU2608644C2 publication Critical patent/RU2608644C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2013125459A 2010-11-03 2011-11-03 Антитела против белка рецептора с-мет RU2608644C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40986610P 2010-11-03 2010-11-03
US61/409,866 2010-11-03
PCT/EP2011/069369 WO2012059561A1 (en) 2010-11-03 2011-11-03 Anti c-met antibodies

Publications (2)

Publication Number Publication Date
RU2013125459A RU2013125459A (ru) 2014-12-10
RU2608644C2 true RU2608644C2 (ru) 2017-01-23

Family

ID=44906140

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2013125459A RU2608644C2 (ru) 2010-11-03 2011-11-03 Антитела против белка рецептора с-мет
RU2013125457/10A RU2013125457A (ru) 2010-11-03 2011-11-03 Комбинация антител против с-мет

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2013125457/10A RU2013125457A (ru) 2010-11-03 2011-11-03 Комбинация антител против с-мет

Country Status (12)

Country Link
US (7) US8637027B2 (https=)
EP (3) EP2635602B1 (https=)
JP (3) JP2013545738A (https=)
CN (2) CN103562223B (https=)
AU (3) AU2011325097B2 (https=)
BR (3) BR112013010688B1 (https=)
CA (2) CA2816745C (https=)
DK (1) DK2635602T3 (https=)
ES (1) ES2594493T3 (https=)
IL (2) IL226112B (https=)
RU (2) RU2608644C2 (https=)
WO (2) WO2012059561A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
EP2143441A1 (en) 2008-07-08 2010-01-13 Pierre Fabre Medicament Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
RU2608644C2 (ru) 2010-11-03 2017-01-23 арДЖЕН-ИКС Н.В. Антитела против белка рецептора с-мет
KR20130036993A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
PT2768857T (pt) * 2011-10-19 2020-01-27 Novimmune Sa Métodos para purificar anticorpos
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
SG11201402485UA (en) 2011-11-21 2014-06-27 Genentech Inc Purification of anti-c-met antibodies
EP2785741A1 (en) * 2011-12-02 2014-10-08 Cancer Research Technology Limited Antibodies against hgf - receptor and uses
US9670275B2 (en) 2012-01-23 2017-06-06 Ablynx N.V. Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors
EP2708556B1 (en) * 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US9535055B2 (en) * 2013-03-28 2017-01-03 Samsung Electronics Co., Ltd. Marker for determining effects of anti-c-Met antibody and method of determining effects of anti-c-Met antibody using the marker
EP2786765B1 (en) * 2013-04-01 2018-10-03 Samsung Electronics Co., Ltd. Composition for combination therapy comprising an anti-C-met antibody and a FGFR inhibitor
KR102139607B1 (ko) * 2013-04-01 2020-07-30 삼성전자주식회사 항 c-Met 항체 및 FGFR 저해제를 포함하는 병용 투여용 약학 조성물
US10214593B2 (en) 2013-04-02 2019-02-26 Samsung Electronics Co., Ltd. Anti-idiotype antibody against anti-c-MET antibody
KR102060540B1 (ko) * 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
CN105452297B (zh) * 2013-04-30 2019-10-11 新加坡科技研究局 mAb 2抗-Met抗体
KR102186363B1 (ko) * 2013-09-06 2020-12-04 삼성전자주식회사 c-Met 저해제 및 베타-카테닌 저해제를 포함하는 병용 투여용 약학 조성물
KR102192591B1 (ko) * 2013-09-09 2020-12-18 삼성전자주식회사 c-Met 저해제 및 c-Myc 저해제를 포함하는 병용 투여용 약학 조성물
KR101811731B1 (ko) * 2014-07-29 2018-01-25 재단법인 아산사회복지재단 Met 저해제에 대한 감수성 예측용 신규한 바이오 마커 및 이의 용도
ES2748295T3 (es) * 2014-09-16 2020-03-16 Symphogen As Anticuerpos anti-MET y composiciones
CN113150147A (zh) * 2015-03-16 2021-07-23 塞尔德克斯医疗公司 抗-met抗体及其使用方法
GB201611123D0 (en) * 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
JP7274413B2 (ja) * 2016-09-23 2023-05-16 マレンゴ・セラピューティクス，インコーポレーテッド ラムダ及びカッパ軽鎖を含む多重特異性抗体分子
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
WO2018221969A1 (en) * 2017-05-30 2018-12-06 Chong Kun Dang Pharmaceutical Corp. A novel anti-c-met antibody and use thereof
JP7325339B2 (ja) * 2017-05-30 2023-08-14 チョン クン ダン ファーマシューティカル コーポレーション 新規な抗ｃ－Ｍｅｔ抗体およびその用途
EP3655026A4 (en) 2017-07-17 2021-07-28 Janssen Biotech, Inc. ANTIGBINDING REGIONS AGAINST FIBRONECTIN TYPE III DOMAINS AND METHOD OF USING THEREOF
CN109771642B (zh) * 2017-11-13 2022-09-20 同济大学苏州研究院 c-MET激动型抗体及其用途
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
BR112021005585A2 (pt) 2018-09-27 2021-06-29 Celgene Corporation proteínas de ligação a sirpa e métodos de uso das mesmas
AU2020349462A1 (en) 2019-09-16 2022-03-03 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging
EP4129335A4 (en) 2020-09-01 2024-04-24 RemeGen Co., Ltd. ANTI C-MET DRUG-ANTIBODY CONJUGATE AND ITS APPLICATIONS
BR112023020801A2 (pt) 2021-04-08 2023-12-12 Byondis Bv Anticorpo ou fragmento de ligação ao antígeno, conjugado anticorpo-fármaco, composição farmacêutica, e, combinação de um anticorpo ou fragmento de ligação ao antígeno, um conjugado anticorpo-fármaco ou uma composição farmacêutica
CN118354789A (zh) * 2021-09-03 2024-07-16 Go医疗股份有限公司 抗糖-cMET抗体及其用途
EP4713360A1 (en) 2023-05-19 2026-03-25 Les Laboratoires Servier Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008142833A (ru) * 2006-03-30 2010-05-10 Новартис АГ (CH) КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ АНТИТЕЛ К c-Met
RU2398777C2 (ru) * 2004-08-05 2010-09-10 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТАГОНИСТЫ, НАПРАВЛЕННЫЕ ПРОТИВ c-met

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5648273A (en) 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
ATE160585T1 (de) 1992-09-18 1997-12-15 Us Gov Health & Human Serv Eine methode zur herstellung von hepatozytwachstumsfaktor und eine zelllinie
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
JP2000515735A (ja) 1996-07-03 2000-11-28 ジェネンテック インコーポレーテッド 肝細胞成長因子レセプターアゴニスト
ITMI20031127A1 (it) 2003-06-05 2004-12-06 Uni Degli Studi Del Piemont E Orientale Am Anticorpi anti-hgf-r e loro uso
CN100538364C (zh) * 2003-06-06 2009-09-09 健泰科生物技术公司 调节HGFβ链和C-MET的相互作用
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
KR100556660B1 (ko) * 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
CA2548282A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
WO2007110698A2 (en) 2005-11-16 2007-10-04 Fariba Nayeri Methods for inhibiting carcinogenesis and/or metastasis in an individual with endogenous c-met ligands and inhibitors
ES2368864T3 (es) 2006-02-06 2011-11-23 Metheresis Translational Research Sa Anticuerpos monoclonales anti-met, sus fragmentos y vectores para el tratamiento de tumores y productos correspondientes.
FR2906533B1 (fr) 2006-09-28 2013-02-22 Pf Medicament Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US20090191580A1 (en) 2007-07-19 2009-07-30 Eisai R & D Management Co., Ltd. METHOD OF SCREENING USING c-MET, A NOVEL SUBSTRATE FOR GAMMA-SECRETASE
US7892770B2 (en) 2007-08-24 2011-02-22 Van Andel Research Institute Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
IL198545A0 (en) 2008-05-14 2011-07-31 Metheresis Translational Res Sa High affinity binding site of hgfr and methods for identification of antagonists thereof
US8455623B2 (en) 2008-05-21 2013-06-04 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US20110165620A1 (en) 2008-05-28 2011-07-07 Roland Romijn Method for the production of proteins or protein fragments
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
WO2010005965A1 (en) 2008-07-08 2010-01-14 Aronchick Craig A Colonic purgative formulations and methods of using the same
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
AR074439A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
RU2608644C2 (ru) 2010-11-03 2017-01-23 арДЖЕН-ИКС Н.В. Антитела против белка рецептора с-мет

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2398777C2 (ru) * 2004-08-05 2010-09-10 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТАГОНИСТЫ, НАПРАВЛЕННЫЕ ПРОТИВ c-met
RU2008142833A (ru) * 2006-03-30 2010-05-10 Новартис АГ (CH) КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ АНТИТЕЛ К c-Met

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OHNO et al., Antigen-binding specificities of antibodies are primarily determined by seven residues of VH, Proc. Natl. Acad. Sci. USA, vol.82, , 1985. RUDIKOFF S. et al., Single amino acid substitution altering antigen-binding specificity, Proc. Natl. Acad. Sci., 1982, 79(6), . *
OHNO et al., Antigen-binding specificities of antibodies are primarily determined by seven residues of VH, Proc. Natl. Acad. Sci. USA, vol.82, реферат, 1985. RUDIKOFF S. et al., Single amino acid substitution altering antigen-binding specificity, Proc. Natl. Acad. Sci., 1982, 79(6), реферат. *

Also Published As

Publication number Publication date
US20170349667A1 (en) 2017-12-07
BR112013010688A2 (pt) 2016-08-09
US20120156206A1 (en) 2012-06-21
US9688773B2 (en) 2017-06-27
US8637027B2 (en) 2014-01-28
WO2012059562A1 (en) 2012-05-10
DK2635602T3 (en) 2016-10-10
CA2816745C (en) 2019-03-12
AU2015210420A1 (en) 2015-09-03
BR112013010687A2 (pt) 2016-08-02
JP2013545738A (ja) 2013-12-26
BR122014027420A2 (pt) 2019-08-20
AU2011325097A1 (en) 2013-05-02
CA2816745A1 (en) 2012-05-10
US20180215833A1 (en) 2018-08-02
IL226113A0 (en) 2013-06-27
EP2635603A1 (en) 2013-09-11
AU2011325097B2 (en) 2015-05-21
US20120148607A1 (en) 2012-06-14
EP2635602A1 (en) 2013-09-11
WO2012059561A1 (en) 2012-05-10
US20150376291A1 (en) 2015-12-31
US20150376292A1 (en) 2015-12-31
AU2011325098A1 (en) 2013-05-09
US20140205606A1 (en) 2014-07-24
JP2016034957A (ja) 2016-03-17
JP2013545455A (ja) 2013-12-26
EP3165538A1 (en) 2017-05-10
EP2635603B1 (en) 2016-03-23
IL226112B (en) 2019-05-30
RU2013125459A (ru) 2014-12-10
US9688774B2 (en) 2017-06-27
JP5857060B2 (ja) 2016-02-10
US9631027B2 (en) 2017-04-25
CN103562223B (zh) 2017-02-22
EP2635602B1 (en) 2016-09-07
CA2816919A1 (en) 2012-05-10
US9884917B2 (en) 2018-02-06
BR112013010688B1 (pt) 2020-11-17
AU2015210420B2 (en) 2017-08-03
ES2594493T3 (es) 2016-12-20
CN103764678A (zh) 2014-04-30
US10676535B2 (en) 2020-06-09
CN103562223A (zh) 2014-02-05
IL226112A0 (en) 2013-06-27
RU2013125457A (ru) 2014-12-10
AU2011325098B2 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
RU2608644C2 (ru) Антитела против белка рецептора с-мет
DK2686347T3 (en) Antibodies against CD70
KR20210141466A (ko) 새로운 cd40 결합 항체
US11261246B2 (en) Anti-IL-22R antibodies
Anna et al. Anti C-met Antibodies-granted patent (Canada)
GB2543729A (en) Antibodies to IL-24

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant
PD4A Correction of name of patent owner
PC41 Official registration of the transfer of exclusive right

Effective date: 20180313